{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T09:53:06Z","timestamp":1793267586457,"version":"4.5.0"},"reference-count":50,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"crossref","award":["JP24fk0108709"],"award-info":[{"award-number":["JP24fk0108709"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"crossref","award":["JP24mk0121297"],"award-info":[{"award-number":["JP24mk0121297"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Japan Science and Technology Agency FOREST Program","award":["JPMJFR205J"],"award-info":[{"award-number":["JPMJFR205J"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Human Vaccines &amp; Immunotherapeutics"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/21645515.2026.2688606","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:58:38Z","timestamp":1783490318000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Safety monitoring of bivalent, quadrivalent, and 9-valent human papillomavirus vaccination in Japan: The vaccine effectiveness, networking, and universal safety (VENUS) study"],"prefix":"10.1080","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1302-9430","authenticated-orcid":false,"given":"Chieko","family":"Ishiguro","sequence":"first","affiliation":[{"name":"Japan Institute for Health Security","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroya","family":"Morita","sequence":"additional","affiliation":[{"name":"Japan Institute for Health Security","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Mimura","sequence":"additional","affiliation":[{"name":"Japan Institute for Health Security","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Tsuzuki","sequence":"additional","affiliation":[{"name":"Japan Institute for Health Security","place":["Tokyo, Japan"]},{"name":"University of Antwerp","place":["Antwerp, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Hirashima-Terada","sequence":"additional","affiliation":[{"name":"Japan Institute for Health Security","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Japan Institute for Health Security","place":["Tokyo, Japan"]},{"name":"Yokohama City University","place":["Yokohama, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Futoshi","family":"Oda","sequence":"additional","affiliation":[{"name":"Kyushu University Graduate School of Medical Sciences","place":["Fukuoka, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Maeda","sequence":"additional","affiliation":[{"name":"Kyushu University Graduate School of Medical Sciences","place":["Fukuoka, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhisa","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Kyushu University Graduate School of Medical Sciences","place":["Fukuoka, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"e_1_3_5_2_1","unstructured":"World Health Organization. Human papillomavirus and cancer. [accessed 2025 Dec 30]. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/human-papilloma-virus-and-cancer."},{"key":"e_1_3_5_3_1","unstructured":"Joint council of vaccine adverse reactions review committee and pharmacovigilance Committee. Minutes of the 2nd meeting on June 14 2013. [in Japanese]. 2013. https:\/\/www.mhlw.go.jp\/stf\/shingi2\/0000091965.html."},{"key":"e_1_3_5_4_1","unstructured":"World Health Organization. Immunization data portal. HPV vaccination program coverage - last dose - females target population who received the last dose of HPV vaccine in the reporting year. 2020. https:\/\/immunizationdata.who.int\/pages\/coverage\/hpv.html?GROUP=WHO%20Regions&ANTIGEN=&YEAR=&CODE=."},{"key":"e_1_3_5_5_1","unstructured":"Ministry of Health. Labour and welfare. Future policy on routine vaccination for human papillomavirus infection (health service bureau notification No. 1126-1) [in Japanese]. 2021 Nov 26. https:\/\/www.mhlw.go.jp\/content\/000875155.pdf."},{"key":"e_1_3_5_6_1","unstructured":"Ministry of Health Labour and Welfare. Cumulative HPV vaccination rate up to the first half of 2024 (document 3-3 105th Health Science council immunization and vaccine subcommittee adverse reactions review committee 10th FY2024 pharmaceutical affairs and food sanitation council drug safety measures subcommittee). 2025 Jan 24. https:\/\/www.mhlw.go.jp\/content\/11120000\/001384279.pdf."},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjph-2024-000982"},{"key":"e_1_3_5_8_1","unstructured":"World Health Organization. Cervical cancer elimination initiative. [accessed 2025 Nov 5]. https:\/\/www.who.int\/initiatives\/cervical-cancer-elimination-initiative."},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.07.073"},{"key":"e_1_3_5_10_1","unstructured":"Center for Biologics Evaluation Research. CBER biologics effectiveness and safety (BEST) system. In: U.S. Food and Drug Administration [internet]. FDA; 2025 Mar 26 [accessed 2025 Dec 24]. https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/cber-biologics-effectiveness-and-safety-best-system."},{"key":"e_1_3_5_11_1","unstructured":"Homepage. In: VAC4EU [Internet]. 2025 Jul 21 [accessed 2025 Dec 24]. https:\/\/vac4eu.org\/."},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biologicals.2024.101750"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m4931"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f5906"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.06.030"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.06.074"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwz284"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5214"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2022.08.069"},{"key":"e_1_3_5_20_1","doi-asserted-by":"crossref","first-page":"428","DOI":"10.2188\/jea.JE20210513","article-title":"The longevity improvement & fair evidence (LIFE) study: overview of the study design and baseline participant profile","volume":"33","author":"Fukuda H","year":"2022","unstructured":"Fukuda H, Ishiguro C, Ono R, Kiyohara K. The longevity improvement & fair evidence (LIFE) study: overview of the study design and baseline participant profile. J Epidemiol. 2022;33:428\u2013437.","journal-title":"J Epidemiol"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad274"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2350091"},{"key":"e_1_3_5_23_1","unstructured":"Ministry of Justice. Japanese law translation: \u201cImmunization Act\u201d (Act No. 68 of 1948) (Amendment of Act No. 103 of 2013). 2016 [accessed 2025 Nov 5]. http:\/\/www.japaneselawtranslation.go.jp\/law\/detail\/?vm=04&re=01&id=2964."},{"key":"e_1_3_5_24_1","unstructured":"Enforcement Order of the immunization Act. Cabinet order no. 197 on 31st July 1948. (Revised on April 1st 2021) [in Japanese]. 2021 [accessed 2025 Nov 5]. https:\/\/elaws.e-gov.go.jp\/document?lawid=323CO0000000197."},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwu322"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-068665"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2022.10.088"},{"key":"e_1_3_5_28_1","volume-title":"Self-controlled case series studies: a modelling guide with R","author":"Farrington P","year":"2021","unstructured":"Farrington P, Whitaker H, Weldeselassie YG. Self-controlled case series studies: a modelling guide with R. Philadelphia (PA): Chapman & Hall\/CRC; 2021."},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5507"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwaa244"},{"key":"e_1_3_5_31_1","unstructured":"World Heath Organization. Prequalification of medical products: package insert (Cervarix). 2009 [accessed 2026 May 15]. https:\/\/extranet.who.int\/prequal\/vaccines\/p\/cervarix-0."},{"key":"e_1_3_5_32_1","unstructured":"World Heath Organization. Prequalification of medical products: package insert (GARDASIL9). 2018 [accessed 2026 May 15]. https:\/\/extranet.who.int\/prequal\/sites\/default\/files\/vwa_vaccine\/FVP-P-306_HPV9_1dose_Merck_PI-2025.pdf."},{"key":"e_1_3_5_33_1","unstructured":"U.S. Food and Drug Administration. Prescribing information (CERVARIX). 2009 [accessed 2026 May 15]. https:\/\/www.fda.gov\/media\/78013\/download?attachment."},{"key":"e_1_3_5_34_1","unstructured":"U.S. Food and Drug Administration. Prescribing information (GARDASIL9). 2014 [accessed 2026 May 15]. https:\/\/www.fda.gov\/media\/90064\/download?attachment."},{"key":"e_1_3_5_35_1","unstructured":"European Medicines Agency. Summary of product characteristics (CERVARIX). 2007 [accessed 2026 May 15]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cervarix-epar-product-information_en.pdf."},{"key":"e_1_3_5_36_1","unstructured":"European Medicines Agency. Summary of product characteristics (Gardasil 9). 2015 [accessed 2026 May 15]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/gardasil-9-epar-product-information_en.pdf."},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2022.11.031"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2023.08.079"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0256379"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2022.100442"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2019-1808"},{"key":"e_1_3_5_42_1","unstructured":"European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) \u2013 product- or population- specific considerations I: vaccines for prophylaxis against infectious diseases EMA\/488220\/2012. 9. 2013 Dec [accessed 2026 May 13]. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-good-pharmacovigilance-practices-gvp-product-or-population-specific-considerations-i-vaccines-prophylaxis-against-infectious-diseases_en.pdf."},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.13350"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2333111"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-024-03538-1"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2025.6425"},{"key":"e_1_3_5_47_1","unstructured":"Digital Agency. Priority policy program for the realization of a digital society. Cabinet decision. 2022 June 7 [accessed 2025 Nov 5]. https:\/\/www.digital.go.jp\/policies\/priority-policy-program-past\/."},{"key":"e_1_3_5_48_1","first-page":"71","article-title":"Effectiveness and safety analysis utilizing the vaccination database [in Japanese]","volume":"47","author":"Japan Institute of Infectious Diseases","year":"2026","unstructured":"Japan Institute of Infectious Diseases. Effectiveness and safety analysis utilizing the vaccination database [in Japanese]. Infect Agents Surveill Rep. 2026;47:71\u201373.","journal-title":"Infect Agents Surveill Rep"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwae071"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5636"},{"key":"e_1_3_5_51_1","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2188\/jea.JE20250095","article-title":"The claims data learning & enhancing for algorithm refinement (CLEAR) study: Overview of the study design and baseline profile","volume":"36","author":"Fukuda H","year":"2025","unstructured":"Fukuda H, Maeda M, Ishiguro C. The claims data learning & enhancing for algorithm refinement (CLEAR) study: Overview of the study design and baseline profile. J Epidemiol. 2025;36:205\u2013211.","journal-title":"J Epidemiol"}],"container-title":["Human Vaccines &amp; Immunotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/21645515.2026.2688606","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/21645515.2026.2688606","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/21645515.2026.2688606","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:59:09Z","timestamp":1783490349000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/21645515.2026.2688606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/21645515.2026.2688606"],"URL":"https:\/\/doi.org\/10.1080\/21645515.2026.2688606","relation":{},"ISSN":["2164-5515","2164-554X"],"issn-type":[{"value":"2164-5515","type":"print"},{"value":"2164-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-04-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-23","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2688606"}}